Roche Pharmaceuticals: its innovative drug Surufuda has officially been approved in China for use in children aged 1 year and above.

On March 6, Roche Pharmaceuticals China announced that its flagship influenza antiviral drug innovation Sufoda granules was officially approved by the China National Medical Products Administration on March 3, 2026. It has been expanded for use in the treatment of children aged 1 to 5 with uncomplicated type A and B influenza, including previously healthy patients and high-risk patients with flu complications.